Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Information source: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Cancer
Intervention: (EORTC QLQ-C30) questionnaire (Behavioral); EuroQol EQ-5D 7-item questionnaire (Behavioral)
Phase: N/A
Status: Recruiting
Sponsored by: Memorial Sloan Kettering Cancer Center Official(s) and/or principal investigator(s): Jeremy Durack, MD, Principal Investigator, Affiliation: Memorial Sloan Kettering Cancer Center
Overall contact: Jeremy Durack, MD, Phone: 212-639-4898
Summary
The purpose of this study is to better understand how effective ablation is for destroying
tumor cells in the kidney and whether quality of life is improved for patients.
Participation in ARMOR may involve retrospective data collection only, combined
retrospective and prospective data collection, or prospective data collection
Clinical Details
Official title: Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Study design: Observational Model: Cohort
Primary outcome: assess renal ablation outcomes
Secondary outcome: differences in imaging characteristicsAssess the progression of imaging findings Radiation exposure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Retrospective enrollment:
- Patients having undergone percutaneous, open or laparoscopic energy ablation of a renal
mass.
Prospective enrollment:
- Patients scheduled to undergo, rather than having undergone, percutaneous, open or
laparoscopic energy ablation of a renal mass.
Exclusion Criteria:
- Patients not having undergone, or considered candidates for percutaneous, open or
laparoscopic energy ablation of a renal mass
- Non-English speaking patients
- Patients under the age of 18.
Locations and Contacts
Jeremy Durack, MD, Phone: 212-639-4898
University of Maryland Medical Center, Baltimore, Maryland 21201, United States; Recruiting Richard Howard, MD Richard Howard, MD, Principal Investigator
Memorial Sloan-Kettering Cancer Center, New York, New York 10065, United States; Recruiting Jeremy Durack, MD, Phone: 212-639-4898 Stephen Solomon, MD, Phone: 212-639-5012 Jeremy Durack, MD, Principal Investigator
Thomas Jefferson University Hospital, Philadelphia,, Pennsylvania 19107, United States; Recruiting Colette Shaw, MD Colette Shaw, MD, Principal Investigator
Rhode Island Hospital, Providence, Rhode Island 02903, United States; Recruiting Damian Dupuy, MD Damian Dupuy, MD, Principal Investigator
Additional Information
Memorial Sloan-Kettering Cancer Center
Starting date: June 2013
Last updated: May 20, 2015
|